The Ramaciotti Foundations are a philanthropic organisation that provides financial support to medical research in Australia.
The Ramaciotti Medal for Excellence is awarded annually to an Australian researcher who has made a significant contribution to biomedical research in Australia. The award is accompanied by a medal and a cash prize of AUD $50,000. The recipient of the award is selected by a panel of experts in biomedical research, who evaluate the nominees based on the quality and impact of their research.
The Ramaciotti Medal for Excellence is considered one of the most prestigious awards in biomedical research in Australia and is highly sought after by researchers in the field.
In 2022, Professor Matthew Kiernan was the recipient of the Ramaciotti Medal for Excellence and the associated $50,000 award. Professor Kiernan is considered one of Australia’s most prominent clinical neurologists and neuroscientists and has received the Ramaciotti Medal in recognition of his extensive research into neurodegenerative disease including dementia and motor neurone disease (amyotrophic lateral sclerosis; MND/ALS).
His extensive record of research into the pathophysiology of MND has resulted in breakthroughs that have changed the management of the disease by physicians worldwide. His research has closed the loop from bench to bedside with technique developments and scientific discoveries translating into greater understanding of the disease and improved patient management.
Professor Kiernan is the Bushell Chair of Neurology and Co-Director of the Brain and Mind Centre at The University of Sydney. He is Professor of Neurology and Staff Specialist at the Royal Prince Alfred Hospital. His work has led to appointments including Chair of the World Federation of Neurology – Motor Neurone Speciality Disease Group, and international recognition through The Forbes Norris Award of the International Alliance of ALS/MND Associations and most recently the Sheila Essey Award of the American Academy of Neurology for significant research contributions in the search for causes, prevention, and cure of ALS.
Australian Health Journal spoke with Professor Kiernan to hear about his journey in medicine and science to try and uncover and understand diseases and his generosity of spirit to pass on what he has learnt.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Addressing Pharmacy challenges at home and abroad
Paul Sinclair’s progression through the ranks of the International Pharmaceutical Federation (FIP) demonstrates the impact and influence he’s had in representing the pharmacy profession on a global scale. In this Australian Health Journal interview, Paul talks about the 4 themes in the upcoming FIP Congress in Brisbane this month. He also talks about the challenges facing pharmacy with remuneration, professional service delivery and the workforce coming out of the COVID era.
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
